Imaging microglial activation in untreated first-episode psychosis: A PET study with [18F]FEPPA

American Journal of Psychiatry

Volumn 174, Issue 2, 2017, Pages 118-124

  Hafizi, Sina ^a,b   Tseng, Huai Hsuan ^a,b   Rao, Naren ^a,b   Selvanathan, Thiviya ^a,b   Kenk, Miran ^a,b   Bazinet, Richard P ^a,b   Suridjan, Ivonne ^a,b   Wilson, Alan A ^a,b   Meyer, Jeffrey H ^a,b   Remington, Gary ^a,b   Houle, Sylvain ^a,b   Rusjan, Pablo M ^a,b   Mizrahi, Romina ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE FEPPA F 18; RADIOLIGAND; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR; ANILIDE; N-(2-((N-(4-PHENOXYPYRIDIN-3-YL)ACETAMIDO)METHYL)PHENOXY)ETHYL FLUORIDE; PYRIDINE DERIVATIVE; TSPO PROTEIN, HUMAN;

ADULT; ANHEDONIA; APATHY; ARTERIAL BLOOD; ARTICLE; BINDING AFFINITY; CELL ACTIVATION; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE DURATION; DISEASE SEVERITY; DORSOLATERAL PREFRONTAL CORTEX; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GRAY MATTER; HIPPOCAMPUS; HUMAN; MALE; MEDIAL PREFRONTAL CORTEX; MICROGLIA; MOLECULAR IMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; REPEATABLE BATTERY ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; VOLUME OF DISTRIBUTION; VOXEL BASED MORPHOMETRY; DIAGNOSTIC IMAGING; GENETICS; GENOTYPE; IMAGE ENHANCEMENT; MULTIMODAL IMAGING; PATHOPHYSIOLOGY; PHYSIOLOGY; PREFRONTAL CORTEX; REFERENCE VALUE; SCHIZOPHRENIA; STATISTICS; YOUNG ADULT;

ADULT; ANILIDES; FEMALE; GENOTYPE; HIPPOCAMPUS; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MICROGLIA; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PSYCHOTIC DISORDERS; PYRIDINES; RECEPTORS, GABA; REFERENCE VALUES; SCHIZOPHRENIA; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 85011559339     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2016.16020171     Document Type: Article

References (55)

1. Kreutzberg GW: Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996; 19:312-318
2. Gehrmann J, Matsumoto Y, Kreutzberg GW: Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev 1995; 20: 269-287
3. CarbonellWS, Murase S, Horwitz AF, et al: Migration of perilesional microglia after focal brain injury and modulation by CC chemokine receptor 5: an in situ time-lapse confocal imaging study. J Neurosci 2005; 25:7040-7047
4. Burguillos MA, Deierborg T, Kavanagh E, et al: Caspase signalling controls microglia activation and neurotoxicity. Nature 2011; 472: 319-324
5. Venneti S, Wiley CA, Kofler J: Imaging microglial activation during neuroinflammation and Alzheimer's disease. J Neuroimmune Pharmacol 2009; 4:227-243
6. Braestrup C, Albrechtsen R, Squires RF: High densities of benzodiazepine receptors in human cortical areas. Nature 1977; 269: 702-704
7. Kamiñska T, Wysocka A, Marmurowska-Michalowska H, et al: Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch Immunol Ther Exp (Warsz) 2001; 49:439-445
8. Nawa H, Takei N: Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci Res 2006; 56:2-13
9. Marx CE, Jarskog LF, Lauder JM, et al: Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia. Biol Psychiatry 2001; 50:743-749
10. Arion D, Unger T, Lewis DA, et al: Molecular evidence for increased expression of genes related toimmuneand chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 2007; 62:711-721
11. Crespo-Facorro B, Carrasco-Marín E, Pérez-Iglesias R, et al: Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: effects of antipsychotic drugs. Psychiatry Res 2008; 158:206-216
12. Maes M, Bosmans E, Ranjan R, et al: Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr Res 1996; 21:39-50
13. Xu HM, Wei J, Hemmings GP: Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia. Br J Psychiatry 1994; 164:251-253
14. Monji A, Kato T, Kanba S: Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 2009; 63: 257-265
15. Stefansson H, Ophoff RA, Steinberg S, et al: Common variants conferring risk of schizophrenia. Nature 2009; 460:744-747
16. Shi J, Levinson DF, Duan J, et al: Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009; 460: 753-757
17. Zuckerman L, Rehavi M, Nachman R, et al: Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology 2003; 28: 1778-1789
18. Meyer U, Nyffeler M, Schwendener S, et al: Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology 2008; 33:441-456
19. Winter C, Reutiman TJ, Folsom TD, et al: Dopamine and serotonin levels following prenatal viral infection in mouse: implications for psychiatric disorders such as schizophrenia and autism. Eur Neuropsychopharmacol 2008; 18:712-716
20. Meyer U, Feldon J: Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. Psychopharmacology (Berl) 2009; 206:587-602
21. Brown AS, Patterson PH: Maternal infection and schizophrenia: implications for prevention. Schizophr Bull 2011; 37:284-290
22. Brown AS, Derkits EJ: Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010; 167:261-280
23. Suvisaari J, Haukka J, Tanskanen A, et al: Association between prenatal exposure to poliovirus infection and adult schizophrenia. Am J Psychiatry 1999; 156:1100-1102
24. Brown AS: Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 2006; 32:200-202
25. Sørensen HJ, Mortensen EL, Reinisch JM, et al: Associationbetween prenatal exposure to bacterial infection and risk of schizophrenia. Schizophr Bull 2009; 35:631-637
26. Meyer U, Schwarz MJ, Müller N: Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther 2011; 132:96-110
27. Kreisl WC, Jenko KJ, Hines CS, et al: A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab 2013; 33:53-58
28. Kurumaji A, Wakai T, Toru M: Decreases in peripheral-type benzodiazepine receptors in postmortem brains of chronic schizophrenics. J Neural Transm (Vienna) 1997; 104:1361-1370
29. Steiner J, Mawrin C, Ziegeler A, et al: Distribution of HLA-DRpositive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol 2006; 112:305-316
30. Doorduin J, De Vries EF, Willemsen AT, et al: Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009; 50: 1801-1807
31. Van Berckel BN, Bossong MG, Boellaard R, et al: Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 2008; 64: 820-822
32. Bloomfield PS, Selvaraj S, Veronese M, et al: Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [11C] PBR28 PET brain imaging study. Am J Psychiatry 2016; 173: 44-52
33. Takano A, Arakawa R, Ito H, et al: Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int J Neuropsychopharmacol 2010; 13:943-950
34. Kenk M, Selvanathan T, Rao N, et al: Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA. Schizophr Bull 2015; 41:85-93
35. Vivash L, O'Brien TJ: Imaging microglial activation with TSPO PET: lighting up neurological diseases? J Nucl Med 2015; 57:165-168
36. Fujita M, Imaizumi M, Zoghbi SS, et al: Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage 2008; 40:43-52
37. Kreisl WC, Fujita M, Fujimura Y, et al: Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage 2010; 49:2924-2932
38. Owen DR, Howell OW, Tang SP, et al: Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood FlowMetab 2010; 30:1608-1618
39. Owen DR, Gunn RN, Rabiner EA, et al: Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med 2011; 52:24-32
40. Owen DR, Yeo AJ, Gunn RN, et al: An 18-kDa translocator protein (TSPO) polymorphismexplains differences in binding affinity of the PET radioligand PBR 28. J Cereb Blood Flow Metab 2012; 32:1-5
41. Mizrahi R, Rusjan PM, Kennedy J, et al: Translocator protein (18 kDa) polymorphism (rs6971) explains in-vivo brain binding affinity of the PET radioligand [(18)F]-FEPPA. J Cereb Blood Flow Metab 2012; 32:968-972
42. Setiawan E, Wilson AA, Mizrahi R, et al: Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 2015; 72:268-275
43. SuridjanI, Pollock BG, VerhoeffNP, et al: In-vivo imaging of greyand white matter neuroinflammation in Alzheimer's disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA. Mol Psychiatry 2015; 20:1579-1587
44. Lyoo CH, Ikawa M, LiowJS, et al: Cerebellumcan serve as a pseudoreference region in Alzheimer disease to detect neuroinflammation measured with PET radioligand binding to translocator protein. J Nucl Med 2015; 56:701-706
45. First M, Spitzer R, Gibbon M, et al: Structured Clinical Interview for DSM-IV Axis I Disorders: Patient Edition (SCIDI/P), Version 2.0. New York, New York State Psychiatric Institute, Biometric Research, 1995
46. Randolph C: Repeatable Battery for the Assessment of Neuropsychological Status. San Antonio, Tex, Psychological Corp, 1998
47. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
48. Rusjan P, Mamo D, Ginovart N, et al: An automated method for the extraction of regional data from PET images. Psychiatry Res 2006; 147:79-89
49. Rusjan PM, Wilson AA, Bloomfield PM, et al: Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography. J Cereb Blood Flow Metab 2011; 31:1807-1816
50. Müller-Gärtner HW, Links JM, Prince JL, et al: Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992; 12:571-583
51. Coughlin JM, Wang Y, Ma S, et al: Regional brain distribution of translocator protein using [(11)C]DPA-713 PET in individuals infected with HIV. J Neurovirol 2014; 20:219-232
52. Khandaker GM, Cousins L, Deakin J, et al: Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2015; 2:258-270
53. Lavisse S, Guillermier M, Hérard A-S, et al: Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. J Neurosci 2012; 32:10809-10818
54. Drugan RC: Peripheral benzodiazepine receptors: molecular pharmacology to possible physiological significance in stress-induced hypertension. Clin Neuropharmacol 1996; 19:475-496
55. RupprechtR, Papadopoulos V, RammesG, et al: Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 2010; 9:971-988